Target intelligence / Profile preview

Pumilio RNA-binding protein 1 (PUM1)

Target
PUM1
Molecular classification
RNA-binding protein, RNA regulatory protein, PUF family protein (Pumilio and FBF family), Post-transcriptional regulator
01

Overview

Pumilio RNA-binding protein 1 (PUM1) is a highly conserved member of the PUF family of RNA-binding proteins. It binds specific sequence motifs ("UGUA") within the 3′ untranslated regions of target mRNAs, regulating their stability, decay, and translation. PUM1 affects embryogenesis, cell development, stem cell self-renewal, and proper differentiation. It is mechanistically integral to cell cycle progression, genome stability, and responses to cellular stress. Dysregulation or mutation of PUM1 is implicated in cancer, neurological disorders such as spinocerebellar ataxia, and abnormal hematopoiesis. Its molecular structure features a signature Pumilio homology domain composed of eight repeats conferring RNA sequence specificity. Therapeutic targeting is in the exploratory stage, with no approved drugs currently.

Other names
Pumilio homolog 1PUM1KIAA0099PUMH1HsPUMPumilio-1HSPUMNEDMSFPUML1SCA47
02

Mechanism of action

Drugs (hypothetical/future) would interfere with RNA binding or modulation of mRNA decay/translation, altering cell-cycle regulation or stem cell maintenance. Experimental modulation could use antisense oligonucleotides, small molecules, or engineered proteins that block/prevent PUM1 interaction with target mRNAs.

03

Biological functions

Post-transcriptional regulation of gene expression by binding 3′ untranslated regions (UTRs) of target mRNAsTranslational repression and activation of specific mRNAsPromotion of mRNA decay (deadenylation and decapping)Regulation of cell cycle progression and genome stabilityMaintenance of stem cell proliferation, pluripotency, and differentiationModulation of processes such as embryogenesis, hematopoiesis, erythropoiesis, and neuronal functionRegulation of immune responses
04

Disease associations

Cancer (promotes tumor cell proliferation, invasion, and immune escape; altered expression in pancreatic, gastric, and hematologic cancers like AML)Neurodegeneration (associated with spinocerebellar ataxia and neuronal integrity disorders)Other proliferative diseasesAbnormal erythropoiesis (e.g., hemoglobin switching)Disorders related to genome instability (e.g., DICER1 syndrome)Preeclampsia and developmental syndromes
05

Safety considerations

Therapeutic targeting may risk genome instability, impaired neuronal integrity, defective hematopoiesis, or altered immune responses due to PUM1's central and multifaceted regulatory roles.Potential developmental and tissue-specific adverse effects if systemically modulated
06

Interacting drugs

None currently established; PUM1 is an emerging target with no approved drugs or chemical probes directly modulating it yet
07

Biomarkers

PUM1 itself is sometimes used as a housekeeping gene reference in gene expression studiesNo established clinical biomarkers for patient selection or efficacy monitoring for therapies targeting PUM1 as of 2024

Beyond the preview

Go deeper on Pumilio RNA-binding protein 1 (PUM1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pumilio RNA-binding protein 1 (PUM1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call